SubsidieMeestersTowArd demoCRatization Of ev-BAsed Therapies
EVerZom aims to revolutionize EV manufacturing with a patented scalable process, targeting GMP compliance and commercial production to lead the European market in clinical applications.
Projectdetails
Introduction
EVerZom has developed a patented, fast, cost-effective, large-scale standardized extracellular vesicles (EV) production process to address the manufacturing issues that hamper EV translation towards the clinic.
Achievements
EVerZom has performed a successful platform scale-up to 6L, meeting quantities needed for phase I trials, placing it at least 2 years ahead of known competitors.
Market Opportunity
With numerous European biotechs poised to enter clinical phase, it’s timely to provide industrial players with EV large-scale capabilities.
Future Goals
EVerZom intends to achieve key milestones during the next 2 years, including:
- Validation of platform GMP compliance at clinical phase I scale.
- Scale-up toward late-stage and commercial batch production.
- Platform expansion usefulness towards different cell lines.
Project Impact
The ACROBAT project will enable us to be aligned with industrial players' roadmap, generate early revenues, and achieve our ambition to be a European pioneer and leader in the EV manufacturing market.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.700.000 |
| Totale projectbegroting | € 2.487.651 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 30-4-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- EVERZOMpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Biosensor Activated Biomanufacturing Scale-upEnduro aims to revolutionize microbial biomanufacturing with its synthetic biology plugin, Enduro Sense, to enable scalable processes and attract investment for commercial deployment. | EIC Accelerator | € 1.815.295 | 2023 | Details |
EUROZIP: European Zinc-Ion PlantThe EUROZIP project aims to scale zinc-ion battery production in Europe, enhancing operational efficiency and sustainability to support the energy transition and meet customer demand. | EIC Accelerator | € 2.500.000 | 2024 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approachAlkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Biosensor Activated Biomanufacturing Scale-up
Enduro aims to revolutionize microbial biomanufacturing with its synthetic biology plugin, Enduro Sense, to enable scalable processes and attract investment for commercial deployment.
EUROZIP: European Zinc-Ion Plant
The EUROZIP project aims to scale zinc-ion battery production in Europe, enhancing operational efficiency and sustainability to support the energy transition and meet customer demand.
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach
Alkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac RepairTOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
High-Throughput Production of Extracellular Vesicles from Organoids under Rotating MotionThe project aims to develop a streamlined system for high-throughput production of extracellular vesicles (EVs) by integrating controlled cell configurations to enhance therapeutic potential. | ERC Proof of... | € 150.000 | 2024 | Details |
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process controlThe SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors. | EIC Pathfinder | € 1.364.281 | 2022 | Details |
Development of a marketable adjuvant candidate for vaccine applicationsADJUVACCINE aims to validate a synthetic platform for scalable production of optimized saponin adjuvants to enhance cost-effective vaccines and attract investment for market entry. | ERC Proof of... | € 150.000 | 2023 | Details |
ScaleTIMEScaleTIME ontwikkelt een schaalbaar productieproces voor microfluïdische cartridges in PoC-diagnostiek door samenwerking tussen MKB-bedrijven en integratie van verschillende technologieën. | Mkb-innovati... | € 87.425 | 2018 | Details |
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair
TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.
High-Throughput Production of Extracellular Vesicles from Organoids under Rotating Motion
The project aims to develop a streamlined system for high-throughput production of extracellular vesicles (EVs) by integrating controlled cell configurations to enhance therapeutic potential.
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.
Development of a marketable adjuvant candidate for vaccine applications
ADJUVACCINE aims to validate a synthetic platform for scalable production of optimized saponin adjuvants to enhance cost-effective vaccines and attract investment for market entry.
ScaleTIME
ScaleTIME ontwikkelt een schaalbaar productieproces voor microfluïdische cartridges in PoC-diagnostiek door samenwerking tussen MKB-bedrijven en integratie van verschillende technologieën.